today announced it will be featured as a presenting company at the H.C. Wainwright 22nd Annual Global Investment Conference.
Biomica’s, a subsidiary of Evogene Ltd., live biotherapeutic drug candidate BMC128 administered in combination with Immune Checkpoint Inhibitors (ICI) significantly improved anti-tumor activity.
Today announced it will be featured as a presenting company at the Crohn’s & Colitis Congress® to be held from today January 21-24, 2021.
The scale-up and GMP batch production is to support the preparation towards the anticipated first in man proof of concept clinical trials
Demonstrating Improved Anti-Tumor Activity Following Treatment with BMC 121 & BMC 127
The company has in-licensed IP and knowhow generated by Prof. Ada E. Yonath, Nobel Prize winner, who will advise Biomica on the program
This is the second program to enter pre-clinical studies; In addition, Prof. David T. Rubin, joins Biomica as a scientific & medical advisor
Aims to augment current cancer therapies by altering patients’ gut microbiome to improve response
This addition to Biomica’s scientific expertise will support the company’s upcoming steps towards its clinical development
